The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies.

Vikas Gupta,Claire Harrison,Elizabeth O Hexner,Haifa Kathrin Al-Ali,Lynda Foltz,Michael Montgomery,William Sun,Prashanth Gopalakrishna,Hagop Kantarjian,Srdan Verstovsek

HAEMATOLOGICA（2016）

引用 47|浏览21

暂无评分

摘要

Myelofibrosis (MF), including primary myelofibrosis (PMF) and MF secondary to essential thrombocythemia (ET) or polycythemia vera (PV), is a chronic Philadelphia chromosome–negative myeloproliferative neoplasm associated with progressive bone marrow fibrosis.[1][1] Many patients with MF experience

查看译文

关键词

JAK inhibitor,anemia,myelofibrosis,overall survival,ruxolitinib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要